BioAtla, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
BCAB Nasdaq 2830 www.bioatla.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BioAtla, Inc.

Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 - May 18th, 2026 4:45 am
BioAtla Announces Share Consolidation - Mar 31st, 2026 2:06 pm
BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - Mar 31st, 2026 2:05 pm
BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets - Mar 2nd, 2026 5:30 am
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) - Dec 31st, 2025 5:00 am
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing - Nov 20th, 2025 10:25 pm
BioAtla Inc (BCAB) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Promising Trial ... - Nov 13th, 2025 10:04 pm
BioAtla (BCAB) Q3 2025 Earnings Call Transcript - Nov 13th, 2025 3:07 pm
BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress - Nov 13th, 2025 2:05 pm
BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas - Nov 7th, 2025 7:00 am
BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025 - Nov 5th, 2025 6:00 am
BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society - Oct 23rd, 2025 6:00 am
BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025 - Oct 3rd, 2025 7:00 am
BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA - Sep 8th, 2025 6:00 am
BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress - Aug 7th, 2025 2:05 pm
BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025 - Aug 4th, 2025 6:00 am